Merck MS tablet set for wider use by NHS in England

Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad.

Mavenclad helps Merck shrug off Rebif decline in MS

Merck's oral MS drug finally gets FDA okay

Merck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after being turned down by the US regulator.